Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Axatilimab by Syndax Pharmaceuticals for Solid Tumor: Likelihood of Approval
Axatilimab is under clinical development by Syndax Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Axatilimab by Syndax Pharmaceuticals for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Axatilimab is under clinical development by Syndax Pharmaceuticals and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...
Axatilimab by Syndax Pharmaceuticals for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Axatilimab is under clinical development by Syndax Pharmaceuticals and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData,...
Axatilimab by Syndax Pharmaceuticals for Graft Versus Host Disease (GVHD): Likelihood of Approval
Axatilimab is under clinical development by Syndax Pharmaceuticals and currently in Pre-Registration for Graft Versus Host Disease (GVHD). According to...
Risk adjusted net present value: What is the current valuation of Incyte's Axatilimab?
Axatilimab is a monoclonal antibody commercialized by Incyte, with a leading Pre-Registration program in Graft Versus Host Disease (GVHD). According...